用于治疗进行性核上性麻痹的胆碱能方法。

Cholinergic approaches to the treatment of progressive supranuclear palsy.

作者信息

Litvan I

机构信息

Neuroepidemiology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

出版信息

J Neural Transm Suppl. 1994;42:275-81. doi: 10.1007/978-3-7091-6641-3_21.

DOI:10.1007/978-3-7091-6641-3_21

PMID:7964692

Abstract

In spite of the severe loss of cholinergic neurons in the brains of patients with progressive supranuclear palsy (PSP), marginal or null benefits are seen in clinical trials after the administration of physostigmine, a cholinesterase inhibitor, or RS-86, a cholinergic agonist. The possible role of cholinergic therapy in PSP is reevaluated.

摘要

尽管进行性核上性麻痹（PSP）患者大脑中的胆碱能神经元严重丧失，但在临床试验中，给予胆碱酯酶抑制剂毒扁豆碱或胆碱能激动剂RS - 86后，仅见轻微益处或无益处。胆碱能疗法在PSP中的可能作用需重新评估。